Mesna
B-cell Non-Hodgkin's Lymphoma
Washington University School of MedicineSmall moleculePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 89/ 100
Competitive context
10 Active assets in the B-cell Non-Hodgkin's Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ifosfamide Shanghai Junshi Bioscience Co., Ltd. | Phase 4 | BBB |
Carboplatin Shanghai Junshi Bioscience Co., Ltd. | Phase 3 | BB |
JS203 Shanghai Junshi Bioscience Co., Ltd. | Phase 2 | B |
Debio 1562 Debiopharm International SA | Phase 2 | B |
Human Cd19Targeted T Cells Hrain Biotechnology Co., Ltd. | Phase 2 | CCC |
View all 13 →
Same molecule, other indications
Mesna is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →